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three-dimensional HepaRG 
spheroids as a liver model to study 
human genotoxicity in vitro with 
the single cell gel electrophoresis 
assay
Marion Mandon1, sylvie Huet1, estelle Dubreil2, Valérie Fessard1 & Ludovic Le Hégarat  1
Many efforts have been made in the last 30 years to develop more relevant in vitro models to study 
genotoxic responses of drugs and environmental contaminants. While 2D HepaRG cells are one of 
the most promising models for liver toxicology, a switch to 3D cultures that integrate both in vivo 
architecture and cell-cell interactions has occurred to achieve even more predictive models. preliminary 
studies have indicated that 3D HepaRG cells are suitable for liver toxicity screening. Our study aimed to 
evaluate the response of HepaRG spheroids exposed to various genotoxic compounds using the single 
cell gel electrophoresis assay. HepaRG spheroids were used at 10 days after seeding and exposed for 
24 and 48 hours to certain selected chemical compounds (methylmethansulfonate (MMS), etoposide, 
benzo[a]pyrene (B[a]P), cyclophosphamide (CPA), 7,12-dimethylbenz[a]anthracene (DMBA), 
2-acetylaminofluorene (2-AAF), 4-nitroquinoline (4-NQO), 2-amino-1-methyl-6-phenylimidazo[4,5-b]
pyridine (PhIP), 2-amino-3-methylimidazo[4,5-f]quinolone (IQ), acrylamide, and 2-4-diaminotoluene 
(2,4-DAT)). After treatment, the comet assay was performed on single cell suspensions and 
cytotoxicity was determined by the ATP assay. Comet formation was observed for all compounds 
except IQ, etoposide and 2,4-DAT. Treatment of spheroids with rifampicin increased CYP3A4 activity, 
demonstrating the metabolic capacity of HepaRG spheroids. These data on genotoxicity in 3D HepaRG 
spheroids are promising, but further experiments are required to prove that this model can improve the 
predictivity of in vitro models to detect human carcinogens.
Information on genetic toxicity is an essential part of the safety assessment for any type of substance. In the 
absence of clear carcinogenic data, genotoxic studies may be useful to conclude on the carcinogenic potential 
of chemical substances. To align with what occurs in humans, in vitro models that closely reflect the structural 
and functional characteristics of human tissues are being developed. Although in vivo studies can investigate the 
genotoxic effects of compounds in different tissues in animals, there are still differences between animals and 
humans, including in the genetic and metabolic systems, which can lead to inconsistent conclusions1.
Considering that most of genotoxic carcinogens in humans require metabolic activation, in vitro cell models 
need to mimic human metabolism as closely as possible, especially concerning the liver. Usually, metabolic acti-
vation is investigated through the addition of an induced rat liver S9 fraction, containing major cytochrome P450 
isoforms and other metabolic enzymes, during in vitro incubations with the compounds2. However, although rel-
evant to elucidate the mode of action of a carcinogenic substance in rodents, the use of a rat liver fraction remains 
questionable to predict mutagenicity in humans, considering species-specific metabolic characteristics. Therefore, 
the development of alternative models that could improve the predictivity of in vitro genotoxicity tests to detect 
human carcinogens without using a rat liver fraction is a challenge for hazard assessment.
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Although the liver is a key organ for xenobiotic detoxification, it is also involved in the bioactivation of var-
ious human carcinogens. Genotoxic metabolites can be formed following one or more steps of phase I and/or 
II metabolism. Therefore, human liver cell models that are metabolically competent are required for in vitro 
genotoxicity testing. To study drug metabolism and toxicity, primary human hepatocytes (PHH) are currently 
considered the gold standard in vitro model3. However, several disadvantages with PHH, including limited avail-
ability, inter-individual variability, and early dedifferentiation to progenitor-like cells lacking relevant hepatic 
gene expression, have been reported1,4. Consequently, immortalized cell lines are commonly used5. Although 
widely used for toxicity studies, the HepG2 hepatoma cell line presents low activities of several drug-metabolizing 
enzymes, especially some cytochrome P450 isoforms6. The well-characterized HepaRG cell line in 2D culture 
depicts a closer phenotype to PHH than HepG2 cells concerning the expression of phase I and II enzymes, trans-
porters, and nuclear factors. This phenotype is stable in culture for several weeks and responds to various induc-
ers7–9. Moreover, this model was shown to be suitable to detect genotoxic compounds with various tests: comet 
assay, micronucleus, γH2AX, as well as genotoxicity-targeted qPCR array2,10–14. However, some promutagen com-
pounds have remained difficult to detect in 2D HepaRG cells, such as styrene and the aromatic amines IQ, MeIQX 
and 2,4-DAT, possibly due to low CYP2E1 and CYP1A2 activities and N-acetyl-, or sulfotransferase (NAT, SULT) 
activities2,13,15.
Although hepatic 2D cell cultures have been widely used to predict in vivo responses to chemicals, they do not 
mimic the complexity of human tissues in vivo16. In fact, 2D liver cell models may have abnormal gene expression 
profiles, and do not share the 3D structure of the liver17,18. To address these limitations, 3D models that promote 
cell-cell and cell-extracellular matrix interactions have been developed and are thus considered more relevant to 
predict in vivo responses. Currently, several 3D in vitro human hepatic systems are available such as matrices and 
scaffolds, bioreactors, and microfluidic cell culture platforms19. However, these systems are technically challeng-
ing, labor intensive, and expensive, and are not suitable for high-throughput applications20. Another method, 3D 
spheroid culture, requires few cells, is easy to handle, and is appropriate for high-throughput studies21,22.
HepG2 spheroids have been reported as a promising model to study in vitro genotoxicity, providing better 
results than 2D monolayer cultures23. In 2017, the development of HepaRG spheroid cultures in ultra-low attach-
ment plates that support spheroidal differentiation was described24. Spheroids maintained a stable phenotype, 
exhibiting several hallmarks of polarized hepatocyte architecture and functions, including metabolizing enzyme 
activities, long-term stable albumin secretion, and transporter localization20,25.Authors showed that 3D HepaRG 
cells express the three major P450 enzymes (CYP1A2, CYP2B6 and CYP3A4) and active hepatic nuclear recep-
tors (AhR, CAR and PXR)24. As this model probably presents the ability to bioactivate xenobiotics due to high 
levels of CYP enzyme activities maintained for up to 28 days, genotoxicity assays on HepaRG spheroids are worth 
developing.
Considering that (i) 2D HepaRG cells have failed to detect some progenotoxic compounds, (ii) 3D HepaRG 
spheroids have shown metabolic activities and functional characteristics that are closer to those of the human 
liver, and (iii) results have shown that the 3D HepG2 model is more sensitive than the 2D model to detect human 
mutagens, we proposed to evaluate the response of HepaRG spheroids exposed to various genotoxic compounds 
using the single cell gel electrophoresis assay (comet assay). We studied the sensitivity of HepaRG spheroids to 
both genotoxicants and pro-genotoxicants, and compared these results to those obtained with 2D differentiated 
HepaRG cells.
Materials and Methods
Chemicals. 2-acetylaminofluorene (2-AAF), 2,4-diaminotoluene (2,4-DAT), 4-nitroquinoline (4-NQO), 
7,12-dimethylbenzaanthracene (DMBA), acrylamide (AA), cyclophosphamide (CPA), dimethylsulfoxide 
(DMSO), etoposide, methylmethanesulfonate (MMS), omeprazole (OME) phenobarbital (PB), rifampicin 
(RIF), phenacetin, diclofenac, bupropion, midazolam, acetaminophen, 4′-OH-diclofenac, 1′-OH-midazolam, 
OH-bupropion, diclofenac-d4 (internal standard), and acetaminophen-d4 (internal standard) were purchased 
from Sigma (Saint-Quentin-Fallavier, France). 2-amino-1-methyl-6-phenylimidazo[4-5b]pyridine (PhIP) and 
2-amino-3-methylimidazo[4-5f]quinolone (IQ) were obtained from Toronto Chemical Research (Toronto, ON, 
Canada).
preparation of the tested compounds. For the comet assay, 11 chemicals were selected. MMS and CPA 
were dissolved in FCS-free medium, 4-NQO, etoposide, AA, 2,4-DAT, DMBA, 2-AAF, PhIP, IQ and B[a]P were 
dissolved in DMSO. For all assays, the final concentration of DMSO never exceeded 0.5%. For CYP induction, 
OME, PB and RIF were dissolved in DMSO.
HepaRG cell culture. Cells were cultured in Williams E medium (Eurobio, Les Ulis, France) supplemented 
with 10% FCS (Perbio, Brebières, France), 100 units/mL penicillin (Invitrogen Corporation, Illkirch, France), 
100 µg/mL streptomycin (Invitrogen Corporation), 5 µg/mL insulin (Sigma-Aldrich, Lyon, France), 2 mM 
L-glutamine (Thermofisher, Waltham, MA, USA), and 25 µg/mL hydrocortisone succinate (Pharmacia & Upjohn, 
Guyancourt, France).
3D HepaRG spheroid formation. 1.106 HepaRG cells were seeded in a 75 cm2 flask and were incubated at 
37 °C with 5% CO2 and medium was changed every 2 days (Fig. 1). After 14 days, cells were trypsinized prior to 
dissociation with a syringe to obtain a suspension of isolated cells. Then, cells were seeded in 96-well ultra-low 
attachment (ULA) plates (Corning, Boulogne-Billancourt, France) at a density of 2,000 cells/well. Medium was 
changed after 7 days and spheroids were used at Day 10.
Comet assay. After 24 or 48 hrs of treatment, medium was removed and spheroids were washed twice with 
PBS. For each condition, 11 spheroids were pooled in a 2 mL Eppendorf. After 5 min of sedimentation, PBS was 
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removed and 200 µL of TrypLETM without red phenol (Gibco, Courtaboeuf, France) at 37 °C was added. After 
40 min of incubation at 37 °C, the dissociation of spheroids was checked under light microscope and cells were 
centrifuged for 5 min at 400 g. TrypLETM was removed and cell pellets were suspended in a pre-warmed low 
melting point agarose (0.5% in PBS) and deposited on conventional microscope slides (initially dipped in 1% 
agarose and dried) as previously described13. The slides were put in a lysis solution (NaCl 2.5 M, EDTA 0.1 M, 
Tris-HCl 10 mM, with extemporaneous addition of DMSO 10% and Triton X-100 1% at pH 10) for 1 hr at 4 °C. 
DNA was allowed to unwind for 40 min in electrophoresis buffer (NaOH 0.3 M, EDTA 1 mM, pH 13) prior to 
electrophoretic migration (0.7 V/cm, 300 mA) for 24 min at room temperature. The slides were incubated twice 
in neutralizing solution (Tris-HCl 0.4 M, pH 7.5) for 5 min and dried for storage with 95% ethanol for 5 min. 
DNA was stained with propidium iodide (2.5 µg/mL in PBS) just before examining the slide with a fluorescence 
microscope (Leica DMR) equipped with a CCD-200E video camera. At least two slides per concentration and 
100 cells per slide were analyzed using Comet Assay IV software (Perceptive Instruments, Haverhill, UK). The 
percentage of DNA in the comet tail (% tail DNA) was used to evaluate the extent of DNA damage. At least three 
independent experiments were conducted.
Cytotoxicity assay. For each treatment condition, one spheroid was used for the cytotoxicity assay. The 
assay was performed using a CellTiter Glo 3D kit (Promega, Charbonnières-les-Bains, France), according to the 
manufacturer’s instructions. ATP luminescence was measured using a Fluostar Optima Microplate reader (BMG 
Labtech, Champigny-sur-Marne, France).
Evaluation of CYPs activities. CYPs activities were determined as previously published26. Briefly, for CYP 
induction, spheroids were incubated with PB (250 µM), RIF (2.5 µM) or OME (50 µM) for 72 hrs, with medium 
renewal each day. After exposure to the genotoxicants, 24 spheroids were pooled and incubated for 4 hrs with 
a cocktail of four substrates: 200 µM phenacetin (CYP1A2), 100 µM bupropion (CYP2B6), 100 µM diclofenac 
(CYP2C9), and 5 µM midazolam (CYP3A4). At the end of this period, 200 µL of medium were mixed with 200 µL 
acetonitrile and samples were stored at −80 °C until analysis.
LC-HRMS conditions. LC-HRMS analysis were performed using an ultra-high pressure liquid chromatog-
raphy (ThermoFisher Scientific, Bremen, Germany) system coupled with an LTQ-Orbitrap XL mass spectrometer 
(ThermoFisher Scientific, Bremen, Germany). Data were acquired and processed with the Xcalibur software, 
version 2.1 (ThermoFisher Scientific). The chromatographic column to separate correctly the metabolites was 
an RX-C8 Zorbax column (2.1 mm, 150 mm, 5 μm, Agilent, Les Ulis, France), protected by a C8 security guard 
system (12.5 mm, 2.1 mm, 5 μm). The flow rate was set at 0.25 mL.min−1. The column was maintained at a tem-
perature of 25 °C in the oven and the samples were refrigerated at 10 °C inside the autosampler. Chromatographic 
separation was carried out applying a gradient between two mobile phase consisting of mobile phase (A): water 
with 0.1% formic acid, and mobile phase (B): pure analytical grade acetonitrile with 0.1% formic acid. The gra-
dient conditions were as follows: from 0 to 6 min ramp linearly from 98 to 10% of mobile phase A, then ramp 
over 0.1 min to initial conditions, and hold for 6 min to re-equilibrate the system. The injection volume was set at 
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Figure 1. 3D HepaRG spheroid culture and treatment schedule for the ATP and comet assays.
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20 μL. The mass spectrometer was operated in electrospray positive ionization mode using the following source 
parameters: capillary voltage 35 V, ion spray voltage 4.5 kV, tube lens 90 V, capillary temperature 350.0 °C, sheath 
gas (nitrogen) flow rate 55 (arbitrary units), auxiliary gas (nitrogen) flow rate 10 (arbitrary units), sweep gas flow 
rate 2 units (arbitrary units). The mass spectrometer instrument was calibrated weekly using a calibration solution 
composed of three mass calibrators to reach mass accuracy below 5 ppm. The instrument method was run in full 
scan mode (FTMS) from m/z 50–800 at a resolving power of 60,000 full width at half maximum (FWHM). The 
accurate masses of metabolites were theoretically calculated for their [M + H]+ species and monitored in samples 
at: m/z 152.0706 for acetaminophen, m/z 256.10999 for OH-bupropion, m/z 342.0804 for OH-midazolam, m/z 
312.0189 for 4′-OH-diclofenac, m/z 156.0957 for acetaminophen-d4, and m/z 300.0491 for diclofenac-d4, with a 
mass tolerance of 5 ppm for quantification purposes.
statistics. All analyses were performed using GraphPad Prism Software (GraphPad Software, Inc., La Jolla, 
CA, USA). Results (medians) of the comet assay from at least three independent experiments were analysed with 
one-way Anova followed by Dunnett’s test. Significance was established as p < 0.05.
Results
3D HepaRG spheroid formation. HepaRG cells seeded at 2,000 cells/per well in 96-well ULA plates aggre-
gated from Day 1 to Day 3 and formed a compact spheroid structure at Day 7 (Fig. 2A). The spheroid diameter 
was around 100 µm and remained unchanged later on. The shape of the spheroids did not change between Day 7 
and Day 21 (Fig. 2B).
CYP activities in 3D HepaRG spheroids. CYP1A2 (100 µM phenacetin), CYP2B6 (100 µM bupropion), 
CYP2C9 (100 µM diclofenac) and CYP3A4 (5 µM midazolam) activities were measured with and without induc-
tion treatment by OME, PB and RIF (Table 1). No CYP1A2 activity was detected in 3D HepaRG spheroids, 
perhaps due to a lack of sensitivity of the LC-HRMS method used. CYP2B6 activity was detected, above the 
D1
D7
D5
D3
A
B
D14D10 D21
Figure 2. 3D HepaRG spheroid. (A) HepaRG cells seeded at 2,000 cells per well in ULA 96-well plates. The 
spheroid-like structure was formed in 7 days. Scale bar = 100 µm. (B) Stability of size and morphology of 
spheroids from Day 10 to Day 21. Scale bar = 100 µm.
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LOD but below the LOQ (0.5 µM), and LOD could be estimated at 1/3 of the LOQ, corresponding to 0.1 pmol/
min-million cells. CYP2C9 activity was detected by the formation of OH-diclofenac at a rate of 1.39 ± 0.54 pmol/
min-million cells. Similarly, CYP3A4 activity was detected with a formation rate of OH-midazolam at 0.41 ± 0.19 
pmol/min-million cells.
Following incubation of 3D HepaRG spheroids with CYP inducers PB or RIF, some CYP activities were 
increased compared to solvent control. A statistically significant increase of CYP2C9 and 3A4 activities by PB 
was not found due to heterogeneous responses from one experiment to the other. RIF increased CYP3A4 activity 
in a statistically significant manner (Table 1). With OME, no CYP induction was observed and instead CYP3A4 
activity was decreased compared to control.
Cytotoxicity assay. For all tested compounds, cytotoxicity was assessed by ATP luminescence measurement 
(Fig. 3). After treatment, one spheroid was used to determine the cytotoxicity of each compound.
No cytotoxicity was found, except for IQ (at 160 and 320 µM, with 68.44% ± 1.281 and 44.15% ± 4.625 cell 
viability, respectively), etoposide (2 µM, 82.90% ± 2.03 cell viability), and PhIP (320 µM, 56.61% ± 9.810 cell 
viability).
Comet assay. The level of DNA damage detected with solvent controls was low, between 0.24 to 2.80% tail 
DNA in 10 different experiments (Fig. 4).
Eleven compounds were tested by the comet assay on 3D HepaRG spheroids (Fig. 4). After 24 hrs exposure, 
MMS and 4-NQO increased the percentage of tail DNA in a concentration-dependent manner with a statistically 
significant difference at 45 and 0.25 µM, respectively. Etoposide failed to induce DNA damage in spheroids after 
24 hrs of treatment up to 2 µM.
The pro-genotoxicants B[a]P, CPA, PhIP, AA, DMBA and 2-AAF significantly induced DNA damage in 
HepaRG spheroids at 20, 1000, 40, 500, 20 and 50 µM, respectively.
IQ failed to induce DNA damage, even at a cytotoxic concentration (320 µM). No significant differences in 
the percentage of tail DNA were found between the control (1.28% ± 0.51) and etoposide (3.94% ± 2.32 for the 
highest concentration) or 2,4-DAT (4.13% ± 1.25 for the highest concentration).
The genotoxicity of these compounds was previously studied in a HepaRG 2D monolayer culture2,12,13. The 
results of the comet assays in both 2D and 3D HepaRG models are compared in Fig. 5. For most compounds, the 
results were similar in the two models, although the Lowest Observed Effecting Concentrations (LECs) of the % 
of tail intensities were always lower on 3D than on 2D models. A discrepant result was observed only for 2-AAF 
which was negative in 2D HepaRG cells but positive in 3D, even for the lowest concentration (0.48% ± 0.12 for the 
control, 3.03% ± 1.04 for 50 µM 2-AAF). IQ and etoposide were negative in the two models.
Discussion
The objective of our study was to adapt the in vitro comet assay for use with 3D HepaRG spheroids and to deter-
mine the capacity of this new 3D model to predict in vivo genotoxicity. Our data demonstrate that the comet assay 
can be performed easily on HepaRG spheroids, and that this 3D model seems suitable to detect the majority of 
pro-genotoxic compounds.
The formation of HepaRG spheroids has previously been described using several different methods: hanging 
drops20, bioreactors25, functional polymers27, and ULA plates24. Among these strategies, spheroids formatted in 
ULA plates were found to be easier to handle and provided reproducible results24. In this previous study, 1,000 to 
2,000 HepaRG cells gave a consistent spheroid size (approximately 150–200 µm), while cell numbers greater than 
2,000 cells formed spheroid structures with a necrotic core and low metabolizing enzyme activities. On the basis 
of findings reported in the literature, we chose to seed 2,000 cells/well, providing spheroids around 100–150 µm 
in size without a necrotic core, contrary to HepG2 spheroids that expand rapidly, with a resulting increasing in 
spheroid diameter28.
Contrary to 2D HepaRG cells that require DMSO to stably express hepatic metabolizing enzymes, 3D HepaRG 
spheroids are cultured free of DMSO but still have enhanced expression of hepatic functional parameters4,24,29. To 
verify the metabolic competence of HepaRG spheroids in our study, we measured CYP enzyme activities through 
the formation rates of metabolites from phenacetin (CYP1A2), bupropion (CYP2B6), diclofenac (CYP2C9) and 
midazolam (CYP3A4), with and without PB and RIF induction. CYP1A2 could not be detected in our conditions, 
even after incubation with CYP inducers, probably due to the low sensitivity of our method. In fact, the LOD 
of acetaminophen was established at 5.8 pmol/min-million cell and the LOQ at 17.36 pmol/min-million cells, 
CYP Substrate Metabolite
CYP activity (pmol/min-million cells)
Control OME PB RIF
CYP1A2 Phenacetin Acetaminophen ND ND ND ND
CYP2B6 Bupropion OH-bupropion <LOQa <LOQb <LOQb <LOQb
CYP2C9 Diclofenac OH-diclofenac 1.39 ± 0.54 1.27 ± 0.46 2.66 ± 2.03 2.38 ± 1.79*
CYP3A4 Midazolam 1′OH-midazolam 0.41 ± 0.19 0.08 ± 0.06 1.35 ± 0.96 1.93 ± 1.54
Table 1. CYP450 activities in 3D HepaRG spheroids. ND: not detected, <LOD corresponding to 1/3 of 
LOQ (Limit of Quantification (µM)), a0.5 µM corresponding to 17.36 pmol/min-million cells; b0.01 µM 
corresponding to 0.35 pmol/min-million cells. OME = omeprazole, PB = phenobarbital, RIF = rifampicin, 
*p < 0.05.
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whereas another study estimated CYP1A2 activity at 12.9 pmol/min-million cells in 3D HepaRG spheroids24. 
Activity of CYP2B6 at 15 pmol/min-million cells was described in 3D HepaRG cells through the formation rate 
of 1-hydroxybupropion24, whereas we detected lower activity (only 0.1 pmol/min-million cells) in our study. 
These discrepancies for CYP1A2 and 2B6 activities between the two studies could be explained by the fact that 
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we determined CYP activities at Day 10 instead of Day 21 as described by Ramaiahgari et al.23. The CYP3A4 and 
CYP2C9 activities were quantified by the formation of 1-OH-midazolam and OH-diclofenac, respectively, and 
a clear increase was observed following PB and RIF induction. Such responses suggest the presence of active 
hepatic nuclear receptors, as previously shown in HepaRG spheroids24.
Our data show that the comet assay can be adapted to 3D HepaRG spheroids. Dissociation from spheroids 
to individual cells is a key step providing good results with no cytotoxicity and a low level of DNA damage when 
using TrypLETM. Positive results were obtained with the direct genotoxic compounds MMS and 4-NQO after 24 
hrs of treatment.
Moreover, 3D HepaRG spheroids were able to metabolize some pro-genotoxicants into genotoxic metabolites, 
giving positive results in the comet assay. CPA, B[a]P, PhIP, 2-AAF, AA and DMBA induced DNA fragmenta-
tion on HepaRG spheroids after 48 hrs of treatment. Only IQ and 2-4D showed negative results in our study. 
Compared to the data published for 2D HepaRG cells2,12,13,15, similar results were obtained with HepaRG sphe-
roids, except for 2-AAF that showed positive results in the comet assay only on the 3D model. However, although 
no DNA damage was detected by the comet assay with 2-AAF on 2D HepaRG cells, the formation of a micro-
nucleus was increased statistically13. HepaRG spheroids seem to be more sensitive to the genotoxic effects of AA 
with a clear concentration increase of DNA damage up to 0.5 mM after 48 hrs of treatment. In 2D HepaRG cells, 
AA was only positive at the highest concentration (5 mM) after 24 hrs of treatment. These results suggest that 
CYP2E1 activity was higher in 3D versus 2D HepaRG models, as previously shown20. Other compounds such as 
styrene and nitrosamines should be tested on HepaRG spheroids to confirm the ability of this 3D model to detect 
CYP2E1-bioactivated genotoxicants.
We failed to observe genotoxicity with 2,4-DAT on the 3D HepaRG model, as previously found on 2D HepaRG 
cells13, suggesting the absence of or a low level of active N-acetyltransferase (NAT) implicated in the activation of 
aromatic amines like IQ, 2-AAF, and 2,4-DAT. A recent study showed that IQ required CYP1A2 in combination 
with NAT2, whereas SULT1A1 did not enhance its genotoxicity30. Nevertheless, as a positive result was obtained 
with 2-AAF, we expect that the 3D HepaRG model possesses at least some NAT activities. Importantly, in the 
comet assay, positive results with 2-AAF were observed on 3 hepatic cell lines (HepG2, HCC1.2, and Huh6), 
whereas IQ was negative in the same cell lines as well as negative in the micronucleus test on HepG2 cells2,31, but 
positive in Huh6 cells32. The genotoxic mechanism of action of IQ in vitro remains unclear: the link between the 
positive response in the comet assay and the formation of DNA-reactive nitrenium ions is hypothetic31. Moreover, 
DNA damage observed in vitro with IQ was probably due to oxidative stress. In fact, DNA damage was observed 
in primary human lymphocytes in the comet assay after 2 hrs of treatment without any metabolic activation sys-
tem, suggesting that IQ induced DNA damage through oxidative stress33. However, HepaRG cells are less sensitive 
to DNA damage induced by oxidative stress than other hepatic cell lines due to high expression of antioxidant 
enzymes2,4,34.
In the present study, etoposide ETO did not affect the percentage of tail DNA, like results obtained with 
2D HepaRG cultures13. These results suggest a low level of DNA topoisomerase II in quiescent HepaRG cells. 
Topoisomerase II enzyme is usually present at high levels in fast-growing cells (e.g. cancer cells) and is particularly 
Chemicals 3D 2D Ref.
COMET LECa COMET LECa
Cyclophosphamide (CPA) + 1 + 0.2 12
Benzo[a]pyrene (B[a]P) + 0.02 +
0.05 12
0.01 2
4-nitroquinoline (4-NQO) + 0.00025 + 0.0025 13
7,12-dimethylbenzanthracene 
(DMBA) + 0.02 + 0.125
12
2-acetylaminefluorene (2-AAF) + 0.05 - 0.5 b 13
2,4-diaminotoluene (2,4-DAT) - 2 b - 10 c 13
Acrylamide (AA) + 0.5 + 5 12
2-amino-3-methylimidazo[4-
5f]quinoline (IQ) - 0.32
b -
0.5 12
0.1 2
2-amino-1-methyl-6-
phenylimidazo[4-5b]pyridine 
(PhIP)
+ 0.04 +
0.04 12
0.05 2
Etoposide - 0.002b - 0.01b 13
Methylmethanesulfonate (MMS) + 0.009 + -c 15
Figure 5. Comparison of comet assay results obtained with 3D and 2D HepaRG cells. −:Negative result; 
+:positive result; LEC: lowest effecting concentration (mM) yielding a positive result in the assay, b highest 
concentration tested, c LEC was not determined in this model.
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important for DNA replication35. The negative response of etoposide ETO in the comet assay both with 3D and 
2D HepaRG cells suggests that topoisomerase II is inactive in these cells, corresponding to the quiescent state of 
differentiated cells. However, etoposide ETO was shown to be genotoxic using the highly predictive qPCR array 
(microarray prediction of 0.97) on 2D HepaRG cells. This result was obtained on a selection of 84 genes after 72 
hrs of treatment with 30 µM ETO every day10. The discrepancy of the results between the two studies could be 
explained by the higher concentration and the longer time of exposure used in the later, as treatment for more 
than 24 hrs could affect the cell cycle of HepaRG cells. Further experiments with others DNA topoisomerase 
inhibitors are required to determine the capacity of this 3D model to detect this kind of compounds.
The cellular response to pro-genotoxic compounds observed depends on the capacity of the cell model to bio-
activate, detoxify and repair DNA damage, and also on the relevance of the genotoxicity test chosen. If we com-
pare the LECs obtained with the comet assay in 3D and 2D HepaRG cells, we find that the LECs are lower with 
the 3D than the 2D cell model for the majority of compounds, especially for AA, DMBA and 2-AAF. However, 
conclusions based on LECs should be drawn with caution because the treatment conditions differed between 
the 2D and 3D models. In fact, only one spheroid of 2,000 HepaRG cells was exposed for 48 hrs to 100 µL of the 
chemical dilutions in 96-well plates, whereas 2D HepaRG cells were seeded in 48-well plates at 210,000 cells/well 
and exposed for 24 hrs to 200 µL of the chemical dilutions. Then, the amount of chemical per cell was 50 times 
higher in 3D conditions than in 2D. Therefore, the comparison of the results between the 2D and 3D models 
should also include the clearances of the chemicals in each condition.
The main objective of our study was to investigate the feasibility of the comet assay on 3D HepaRG spheroids 
to improve the in vitro detection of human genotoxic compounds. Taken together, the data obtained indicate that 
this model could be suitable to detect human pro-carcinogens, in particular compounds bioactivated through 
CYP2E1 and 1A2. Nonetheless, more data on the characterization of xenobiotic metabolism in 3D HepaRG 
spheroids are required. Interestingly, several studies have shown that 3D models of PHH, HepaRG and HepG2 
cells were more predictive than 2D for hepatotoxicity24,36–40. The major weakness for using the classical comet 
assay on the 3D HepaRG model is the low number of cells contained in one spheroid. In order to reduce the 
number of spheroids to pool and to improve both reproducibility and throughput, it could be worth adapting the 
CometChip Platform, which has been validated with 2D cultures, on 3D models41. A recent study also showed 
promising results for the micronucleus test using HepG2 3D models with B[a]P and PhIP23. Contrary to HepG2 
spheroids, the absence of cell division in 3D HepaRG spheroids will need to be overcome to adapt the micronu-
cleus assay.
In conclusion, we first report here the adaption of the comet assay in 3D HepaRG spheroids. We showed that 
3D HepaRG spheroids are also an attractive model for in vitro genotoxicity testing and further experiments are 
required to prove that this model can improve the predictivity of in vitro models to detect human carcinogens.
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